Malaria Information and Prophylaxis, by Country [U]
|Country||Areas with Malaria||Drug Resistance2||Malaria Species3||Recommended Chemoprophylaxis4||Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries|
|Uganda||All||Chloroquine||P. falciparum >85%,
remainder P. malariae, P. ovale, and P. vivax
|Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6|
|Ukraine||None||Not Applicable||Not Applicable||Not Applicable|
|United Arab Emirates||None||Not Applicable||Not Applicable||Not Applicable|
|United Kingdom (with Channel Islands and Isle of Man)||None||Not Applicable||Not Applicable||Not Applicable|
|United States||None||Not Applicable||Not Applicable||Not Applicable|
|Uruguay||None||Not Applicable||Not Applicable||Not Applicable|
|Uzbekistan||None||Not Applicable||Not Applicable||Not Applicable|
1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
6. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.